TearClear is a clinical stage ophthalmic pharmaceutical business that is transforming trusted drugs into best-in-class therapies. The company’s glaucoma portfolio offers patients preservative-free doses delivered directly from preserved solutions. The lead candidate is nearing Pivotal Study completion for approval in the US with three candidates swiftly following.
Current preserved medications for chronic eye diseases are known to exacerbate ocular surface disease (OSD). Often times, glaucoma patients rely on a daily drop regimen of one, or multiple, drugs that contain the preservative benzalkonium chloride (BAK). BAK is the most common preservative found in 70% of ophthalmic drugs. With its trusted and proven ability to keep the solution sterile, BAK is beneficial and important in the bottle. However, on the ocular surface, BAK is attributed to adverse events that contribute to OSD such as hyperemia, superficial punctate keratitis (SPK), and conjunctival inflammation.
While preserved drugs are commonly prescribed to treat chronic diseases, long term use often results in a further compromised ocular surface. TearClear is addressing the intersection where this occurs, where glaucoma and OSD meet.
The Company has completed two in-human pilot studies, both of which demonstrated safety and efficacy. As TearClear’s first product proceeds toward US regulatory approval, new drugs beyond glaucoma have demonstrated success with our innovation and more continue to be validated.